Loading stock data…
Natera, Inc. (NTRA)
$272.31+10.40 (+3.97%)
After Hours$272.31+0.00 (+0.00%)· Last close Jun 29
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Natera, Inc. in the Healthcare sector is trading at $272.31 with a market capitalization of $30.3B. Wall Street consensus targets $262.67 (21 analysts), implying a -3.5% move over the next 12 months. The stock is currently near its 52-week high of $274.86, remaining 30.2% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $696.64M↑ | $665.50M↑ | $592.18M↑ | $546.60M↑ | $501.83M |
| Gross Profit | $450.83M↑ | $445.43M↑ | $384.38M↑ | $346.60M↑ | $316.76M |
| Operating Income | -$93.52M↓ | -$22.79M↑ | -$97.58M↑ | -$110.37M↓ | -$79.18M |
| Net Income | -$85.09M↓ | $47.26M↑ | -$87.54M↑ | -$100.94M↓ | -$66.94M |
Peer Comparison
JNJUNHPFE
Fundamentals
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of tre...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$30.34B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.57
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-12.76%
Volume
Today's trading volume
1.73M
Recent News
Medical Services Name Tests For Colon Cancer. Natera Stock Hits A High.
Natera stock got a boost from an analyst's price target hike and new partnership news, lifting shares to a record high Monday. The medical services stock had a powerful breakout last week on the company's positive news on its colon cancer test, and is in the buy zone of a cup base. Natera's constructive chart action and its three-year sales growth rate of 45% make it Monday's IBD 50 Growth Stocks To Watch choice.
U.S. Supreme Court Rejects CareDxA’s Appeal in Natera, Inc. (NTRA) False-advertising Dispute
Natera, Inc. (NASDAQ:NTRA) is among the Best Healthcare Stocks. On June 1, Reuters reported that the U.S. Supreme Court declined to hear CareDx’s appeal in its false-advertising dispute with Natera, Inc. (NASDAQ:NTRA). It left intact lower-court rulings that denied CareDx damages over claims involving kidney transplant tests. Reuters said the justices declined to review whether […]
Natera (NTRA) Stock Jumps 10.7%: Will It Continue to Soar?
Natera (NTRA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
US Stock Market Today S&P 500 Futures Edge Higher On Cooler Yields Data
The Morning Bull - US Market Morning Update Thursday, Jun, 25 2026 US stock futures are slightly higher this morning, with E-mini S&P 500 contracts up about 0.1%, as investors weigh cooler bond yields against mixed signals on growth and inflation. US Treasury yields have edged lower after progress in US–Iran talks, which matters because cheaper government borrowing can ease pressure on mortgage rates and business loans. At the same time, the S&P Global US Manufacturing PMI at 55.7 and the...
Natera Flashes A Buy Signal. Why Shares Just Leaped By Double Digits.
Natera stock narrowly broke out Wednesday after Japan's regulators approved its Signatera test to scan for colon cancer.